Synlogic Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Synlogic stock.
View analyst ratings for Synlogic or view top-rated stocks.

5 equities research analysts have issued 1 year price targets for Synlogic's stock. Their SYBX stock forecasts range from $6.00 to $9.00. On average, they predict Synlogic's stock price to reach $7.80 in the next year. This suggests a possible upside of 635.8% from the stock's current price.
View analysts' price targets for Synlogic or view top-rated stocks among Wall Street analysts.

Synlogic's stock was trading at $2.42 at the beginning of 2022. Since then, SYBX shares have decreased by 56.2% and is now trading at $1.06.
View the best growth stocks for 2022 here.

Synlogic is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Synlogic.

Synlogic, Inc. (NASDAQ:SYBX) posted its earnings results on Thursday, May, 12th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The biotechnology company earned $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. Synlogic had a negative trailing twelve-month return on equity of 43.07% and a negative net margin of 3,067.42%. During the same quarter in the previous year, the business earned ($0.36) EPS.
View Synlogic's earnings history.

Shares of Synlogic reverse split on the morning of Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

Some companies that are related to Synlogic include OrganiGram (OGI), Precigen (PGEN), Theratechnologies (THERF), Omeros (OMER), Lexicon Pharmaceuticals (LXRX), CytoDyn (CYDY), Biotech Acquisition (BIOT), AC Immune (ACIU), Alaunos Therapeutics (TCRT), Heron Therapeutics (HRTX), Pliant Therapeutics (PLRX), Aadi Bioscience (AADI), Alpine Immune Sciences (ALPN), Verona Pharma (VRNA) and Prelude Therapeutics (PRLD).
View all of SYBX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYBX stock can currently be purchased for approximately $1.06.

Synlogic (NASDAQ:SYBX) has a market capitalization of $74.47 million and generates $1.75 million in revenue each year. The biotechnology company earns $-60.56 million in net income (profit) each year or ($1.00) on an earnings per share basis.

Synlogic employs 84 workers across the globe.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The official website for Synlogic is www.synlogictx.com. The biotechnology company can be reached via phone at (617) 401-9975, via email at liz@synlogictx.com, or via fax at 512-681-5201.